We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 1AFX market cap is 5.17B. The company's latest EPS is EUR 1.9983 and P/E is 30.68.
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 1.34B | 1.65B | 1.9B | 2.09B | 2.07B |
| Operating Income | 177.55M | 373.61M | 396.88M | 348.12M | 194.45M |
| Net Income | 122.39M | 236.28M | 293.91M | 290.4M | 178.73M |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 2.01B | 2.4B | 2.82B | 3.03B | 3.39B |
| Total Liabilities | 562.73M | 718.59M | 792.73M | 860.02M | 1.34B |
| Total Equity | 1.45B | 1.68B | 2.03B | 2.17B | 2.06B |
| Year End 30 September 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 178.53M | 362.66M | 188.2M | 250.86M | 247.32M |
| Investing | -71.95M | -75.2M | -148.89M | -110.98M | -412.31M |
| Financing | -122.96M | -285.89M | -38.24M | -135.09M | 176.25M |
| Market Cap | 5.17B |
| Price to Earnings Ratio | 30.68 |
| Price to Sales Ratio | 2.65 |
| Price to Cash Ratio | 270.28 |
| Price to Book Ratio | 2.67 |
| Dividend Yield | 1.04% |
| Shares Outstanding | 89.44M |
| Average Volume (1 week) | 431 |
| Average Volume (1 Month) | 279 |
| 52 Week Change | -52.39% |
| 52 Week High | 122.25 |
| 52 Week Low | 44.36 |
| Spread (Intraday) | 0.45 (0.79%) |
| Company Name | Carl Zeiss Meditec AG |
| Address |
goeschwitzer str. 51-52 jena 07745 |
| Website | https://www.zeiss.de |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
